Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028

Reuters09-27

Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028

**Journey Medical Corporation Extends and Amends $25 Million Loan Facility** Journey Medical Corporation has announced it entered into a Third Amendment to its existing credit agreement with SWK Funding LLC and other financial institutions on September 25, 2025. The amendment extends the maturity date of its $25 million term loan from December 27, 2027, to June 27, 2028. The revised agreement also adjusts the principal repayment schedule: starting February 2026, Journey Medical must make quarterly repayments equal to 7.5% of the funded loan principal. However, if the company surpasses $60 million in trailing twelve-month revenue by December 31, 2025, repayments are deferred until February 2027, increasing to 10% of the principal per quarter. The amendment aims to provide Journey Medical with greater financial flexibility as it continues its operations and growth initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-093891), on September 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2570320448?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-27 04:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570320448","market":"us","top_or_hot":-1,"title":"Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Journey Medical Corporation Extends and Amends $25 Million Loan Facility** Journey Medical Corporation has announced it entered into a Third Amendment to its existing credit agreement with SWK Funding LLC and other financial institutions on September 25, 2025. The amendment extends the maturity date of its $25 million term loan from December 27, 2027, to June 27, 2028. The revised agreement also adjusts the principal repayment schedule: starting February 2026, Journey Medical must make quarterly repayments equal to 7.5% of the funded loan principal. However, if the company surpasses $60 million in trailing twelve-month revenue by December 31, 2025, repayments are deferred until February 2027, increasing to 10% of the principal per quarter. The amendment aims to provide Journey Medical with greater financial flexibility as it continues its operations and growth initiatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-093891), on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJourney Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-27 04:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Journey Medical Corporation Extends and Amends $25 Million Loan Facility** Journey Medical Corporation has announced it entered into a Third Amendment to its existing credit agreement with SWK Funding LLC and other financial institutions on September 25, 2025. The amendment extends the maturity date of its $25 million term loan from December 27, 2027, to June 27, 2028. The revised agreement also adjusts the principal repayment schedule: starting February 2026, Journey Medical must make quarterly repayments equal to 7.5% of the funded loan principal. However, if the company surpasses $60 million in trailing twelve-month revenue by December 31, 2025, repayments are deferred until February 2027, increasing to 10% of the principal per quarter. The amendment aims to provide Journey Medical with greater financial flexibility as it continues its operations and growth initiatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-093891), on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4164","symbol_name":"特殊金融服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL3fvpgR:1","article_id":"2570320448","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570320448","pubTimestamp":1758919190,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Journey Medical Corporation Extends and Amends $25 Million Loan Facility** Journey Medical Corporation has announced it entered into a Third Amendment to its existing credit agreement with SWK Funding LLC and other financial institutions on September 25, 2025. The amendment extends the maturity date of its $25 million term loan from December 27, 2027, to June 27, 2028. The revised agreement also adjusts the principal repayment schedule: starting February 2026, Journey Medical must make quarterly repayments equal to 7.5% of the funded loan principal. However, if the company surpasses $60 million in trailing twelve-month revenue by December 31, 2025, repayments are deferred until February 2027, increasing to 10% of the principal per quarter. The amendment aims to provide Journey Medical with greater financial flexibility as it continues its operations and growth initiatives.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4164":"特殊金融服务","DERM":"Journey Medical Corp","BK4007":"制药","SWKH":"SWK Holdings Corp"},"translate_title":"Journey Medical Corporation修改信贷协议，将2500万美元定期贷款到期日延长至2028年6月","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SWKH":0.9,"DERM":0.9},"content_text":"Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028\n    \n\n        **Journey Medical Corporation Extends and Amends $25 Million Loan Facility** Journey Medical Corporation has announced it entered into a Third Amendment to its existing credit agreement with SWK Funding LLC and other financial institutions on September 25, 2025. The amendment extends the maturity date of its $25 million term loan from December 27, 2027, to June 27, 2028. The revised agreement also adjusts the principal repayment schedule: starting February 2026, Journey Medical must make quarterly repayments equal to 7.5% of the funded loan principal. However, if the company surpasses $60 million in trailing twelve-month revenue by December 31, 2025, repayments are deferred until February 2027, increasing to 10% of the principal per quarter. The amendment aims to provide Journey Medical with greater financial flexibility as it continues its operations and growth initiatives.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-093891), on September 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2570320448","isCrawlerRequest":true}